Citius Oncology Inc (CTOR)

Currency in USD
1.19
+0.02(+1.69%)
Real-time Data·
CTOR is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.141.19
52 wk Range
0.556.19
Key Statistics
Prev. Close
1.17
Open
1.16
Day's Range
1.14-1.19
52 wk Range
0.55-6.19
Volume
52.04K
Average Volume (3m)
465.61K
1-Year Change
-0.8333%
Book Value / Share
0.69
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CTOR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
6.00
Upside
+404.20%
Members' Sentiments
Bearish
Bullish
ProTips
Short term obligations exceed liquid assets

Citius Oncology Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Citius Oncology Inc Company Profile

Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. is a subsidiary of Leonard-Meron Biosciences, Inc.

Compare CTOR to Peers and Sector

Metrics to compare
CTOR
Peers
Sector
Relationship
P/E Ratio
−4.4x−5.2x−0.5x
PEG Ratio
−0.52−0.080.00
Price/Book
1.8x2.1x2.6x
Price / LTM Sales
26.4x53.1x3.3x
Upside (Analyst Target)
-66.3%45.6%
Fair Value Upside
Unlock−4.5%4.9%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 6.00
(+404.20% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Maxim Group
Buy6.00+404.20%-UpgradeSep 23, 2025
Maxim Group
Hold---DowngradeMay 23, 2025

Earnings

Latest Release
Feb 13, 2026
EPS / Forecast
-0.06 / -0.02
Revenue / Forecast
3.94M / --
EPS Revisions
Last 90 days

CTOR Income Statement

People Also Watch

4.85
ROLR
+8.02%
1.60
ACRV
+0.31%
2.050
MAIA
-1.44%
12.100
BDSX
-3.74%
2.320
CNTX
0.00%

FAQ

What Is the Citius Oncology (CTOR) Stock Price Today?

The Citius Oncology stock price today is 1.19

What Stock Exchange Does Citius Oncology Trade On?

Citius Oncology is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Citius Oncology?

The stock symbol for Citius Oncology is "CTOR."

What Is the Citius Oncology Market Cap?

As of today, Citius Oncology market cap is 103.28M.

What Is Citius Oncology's Earnings Per Share (TTM)?

The Citius Oncology EPS (TTM) is -0.31.

From a Technical Analysis Perspective, Is CTOR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Citius Oncology Stock Split?

Citius Oncology has split 0 times.

What is the current trading status of Citius Oncology (CTOR)?

As of Feb 19, 2026, Citius Oncology (CTOR) is trading at a price of 1.19, with a previous close of 1.17. The stock has fluctuated within a day range of 1.14 to 1.19, while its 52-week range spans from 0.55 to 6.19.

What Is Citius Oncology (CTOR) Price Target According to Analysts?

The average 12-month price target for Citius Oncology is USD6.00, with a high estimate of USD6 and a low estimate of USD6. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +404.20% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.